美国斯坦福大学Maximilian Diehn等研究人员实现免疫检查点抑制对治疗益处的非侵入性早期识别。2020年10月1日,《细胞》杂志在线发表了这项成果。
Title: Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Author: Barzin Y. Nabet, Mohammad S. Esfahani, Everett J. Moding, Emily G. Hamilton, Jacob J. Chabon, Hira Rizvi, Chloe B. Steen, Aadel A. Chaudhuri, Chih Long Liu, Angela B. Hui, Diego Almanza, Henning Stehr, Linda Gojenola, Rene F. Bonilla, Michael C. Jin, Young-Jun Jeon, Diane Tseng, Cailian Liu, Taha Merghoub, Joel W. Neal, Heather A. Wakelee, Sukhmani K. Padda, Kavitha J. Ramchandran, Millie Das, Andrew J. Plodkowski, Christopher Yoo, Emily L. Chen, Ryan B. Ko, Aaron M. Newman, Matthew D. Hellmann, Ash A. Alizadeh, Maximilian Diehn
Issue&Volume: 2020-10-1
Abstract: Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors(ICIs) can produce remarkably durable responses, most patients develop early diseaseprogression. Furthermore, initial response assessment by conventional imaging is oftenunable to identify which patients will achieve durable clinical benefit (DCB). Here,we demonstrate that pre-treatment circulating tumor DNA (ctDNA) and peripheral CD8T cell levels are independently associated with DCB. We further show that ctDNA dynamicsafter a single infusion can aid in identification of patients who will achieve DCB.Integrating these determinants, we developed and validated an entirely noninvasivemultiparameter assay (DIREct-On, Durable Immunotherapy Response Estimation by immuneprofiling and ctDNA-On-treatment) that robustly predicts which patients will achieveDCB with higher accuracy than any individual feature. Taken together, these resultsdemonstrate that integrated ctDNA and circulating immune cell profiling can provideaccurate, noninvasive, and early forecasting of ultimate outcomes for NSCLC patientsreceiving ICIs.
DOI: 10.1016/j.cell.2020.09.001
Source: https://www.cell.com/cell/fulltext/S0092-8674(20)31142-9